PTC Therapeutics, Inc. (PTCT) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 1.01B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $1.01B | (m) | (m) |
| 2026-03-31 | (m) | $827.11M | (m) | (m) |
| 2025-12-31 | (m) | $1.73B | (m) | (m) |
| 2025-09-30 | (m) | $1.78B | (m) | (m) |
| 2025-06-30 | (m) | $1.76B | (m) | (m) |
| 2025-03-31 | (m) | $1.77B | (m) | (m) |
| 2024-12-31 | (m) | $806.78M | (m) | (m) |
| 2024-09-30 | (m) | $900.66M | (m) | (m) |
| 2024-06-30 | (m) | $900.45M | (m) | (m) |
| 2024-03-31 | (m) | $927.56M | (m) | (m) |
| 2023-12-31 | (m) | $937.82M | (m) | (m) |
| 2023-09-30 | (m) | $798.18M | (m) | (m) |
| 2023-06-30 | (m) | $818.73M | (m) | (m) |
| 2023-03-31 | (m) | $770.45M | (m) | (m) |
| 2022-12-31 | (m) | $698.80M | (m) | (m) |
| 2022-09-30 | (m) | $696.62M | (m) | (m) |
| 2022-06-30 | (m) | $618.24M | (m) | (m) |
| 2022-03-31 | (m) | $569.39M | (m) | (m) |
| 2021-12-31 | (m) | $538.59M | (m) | (m) |
| 2021-09-30 | (m) | $492.23M | (m) | (m) |
| 2021-06-30 | (m) | $471.89M | (m) | (m) |
| 2021-03-31 | (m) | $430.45M | (m) | (m) |
| 2020-12-31 | (m) | $380.77M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $306.98M | $12.13M | (m) |
| 2019-09-30 | (m) | (m) | $12.35M | (m) |
| 2018-12-31 | (m) | $264.73M | (m) | (m) |
| 2018-03-31 | (m) | $223.91M | (m) | (m) |
| 2017-12-31 | (m) | $194.39M | (m) | (m) |
| 2017-09-30 | (m) | $141.55M | (m) | (m) |
| 2017-06-30 | (m) | $122.69M | (m) | (m) |
| 2017-03-31 | (m) | $90.36M | (m) | (m) |
| 2016-12-31 | (m) | $82.70M | (m) | (m) |
| 2016-09-30 | (m) | $70.25M | (m) | (m) |
| 2016-06-30 | (m) | $57.04M | (m) | (m) |
| 2016-03-31 | (m) | $48.18M | (m) | (m) |
| 2015-12-31 | (m) | $36.77M | (m) | (m) |
| 2015-09-30 | (m) | $36.69M | (m) | (m) |
| 2015-06-30 | (m) | $28.61M | (m) | (m) |
| 2015-03-31 | (m) | $23.51M | (m) | (m) |
| 2014-12-31 | (m) | $25.25M | (m) | (m) |
| 2014-09-30 | (m) | $17.00M | (m) | (m) |
| 2014-06-30 | (m) | $31.59M | (m) | (m) |
| 2014-03-31 | (m) | $36.77M | (m) | (m) |
| 2013-12-31 | (m) | $34.70M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $28.56M | (m) | (m) |
| 2012-12-31 | (m) | $33.95M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $105.41M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |